The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced it has submitted initial results of the Company’s prospective, open labeled, clinical trial assessing the CompuFlo® technology in correctly identifying the epidural space during an epidural procedure to a prestigious American pain management society in advance of this organization’s annual meeting in 2016.
The Company designed the study, in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space.
Study results suggested that the non-invasive CompuFlo technology was able in a real time to objectively and accurately identify the epidural space when compared to radiological X-ray based fluoroscopy. Data suggested that the CompuFlo® technology has the potential to effectively avoid exposure of the patient to radiation.
The Board of Directors of the Issuer is pleased to submit the initial results of our clinical trial and look forward to fully disclosing the data at this prestigious organization’s annual meeting early next year.
Legal basis: § 3 subparagraph 1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market".
Osoby reprezentujące spółkę:
Joseph D'Agostino - CFO